{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-003649","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.662073+00:00","generated_at":"2026-06-20T00:04:00.577509+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pulmatrix doses first patient in Phase 2b trial of PUR1900 for ABPA with asthma","bullets":["First patient dosed in randomized, double-blind, placebo-controlled Phase 2b study of inhaled itraconazole (PUR1900) for ABPA in asthma.","Study targets 30 subjects across US, UK, Australia, France; 3 arms: placebo, 20 mg, 40 mg daily for 16 weeks plus 8-week follow-up.","Partnership with Cipla; proof-of-concept data expected by mid-2024.","PUR1900 aims to be first approved ABPA treatment, reducing systemic side effects of oral antifungals."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-003649","json":"https://secwatch.observer/filing/0001493152-23-003649.json","markdown":"https://secwatch.observer/filing/0001493152-23-003649.md","text":"https://secwatch.observer/filing/0001493152-23-003649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223003649/0001493152-23-003649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223003649/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T00:04:00.577509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}